Investigations of clofibrate in alternative carcinogenicity models.
Santostefano
Michael J
MJ
GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina 27709, USA. michael.j.santostefano@gsk.com
Hoivik
Debie J
DJ
Miller
Richard T
RT
D000818:Animals; D000831:Animals, Newborn; D015197:Carcinogenicity Tests / Q000379:methods*; D002994:Clofibrate / Q000008:administration & dosage / Q000633:toxicity*; D004195:Disease Models, Animal; D005260:Female; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D047493:PPAR alpha / Q000819:agonists; D020025:Peroxisome Proliferators / Q000633:toxicity*; D012680:Sensitivity and Specificity; D013997:Time Factors
D047493:PPAR alpha; D020025:Peroxisome Proliferators; D002994:Clofibrate